Zika vaccine induces strong immune response in three phase 1 studies

08-Dec-2017 - Three Phase 1 human clinical trials evaluating an Army-developed Zika purified inactivated virus (ZPIV) vaccine have shown it was safe and well-tolerated in healthy adults and induced a robust immune response. Each of the three studies included in the paper was designed to address a unique ...

Sanofi Pasteur, Fiocruz, and WRAIR agree to collaborate on Zika vaccine research

28-Oct-2016 - Sanofi and its vaccines global business unit Sanofi Pasteur, announced that it has agreed to Principles of Collaboration with the Oswaldo Cruz Foundation-- by means of its Immuno- biological Technology Institute known as Bio-Manguinhos/Fiocruz-and the Walter Reed Army Institute of Research ...

First discovery in United States of colistin resistance in a human E. coli infection

30-May-2016 - The Multidrug Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR) characterized a transferrable gene for colistin resistance in the United States that may herald the emergence of truly pan-drug resistant bacteria. Colistin is the ...

Avantogen’s Hawaii Biotech Inc. receives clinical trial support from Walter Reed Army Institute of Research

03-Sep-2008 - Avantogen Ltd announced additional support for the Dengue vaccine program developed by Hawaii Biotech Inc, in which Avantogen holds a significant investment stake. The Dengue clinical trial will be conducted as part of a broader trial at the clinical trials centre of the US Walter Reed Army ...

Walter Reed Army Institute and Siam Life Science Develop New Gold Standard for Pharmacological and Toxicological Test Systems

Siam Life Science Secures Exclusive License For Unique Liver Cell Line From Walter Reed Army Institute Of Research

23-May-2008 - A breakthrough technology in the form of a unique, functional human liver cell line has the potential to become the new worldwide gold standard for preclinical drug evaluation studies. The cell line, licensed by Thailand-based human cell technology company, Siam Life Science Ltd. (SLS), was ...

Crucell and WRAIR Sign CRADA to Evaluate PER.C6® Technology for Development of Flavivirus Vaccines

27-Dec-2005 - Crucell N.V. announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) to evaluate Crucell's PER.C6® technology for the development of vaccines against the flaviviruses dengue fever and Japanese encephalitis ...